Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2014 09:51 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research

PHILADELPHIA, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that it has received a new research report (dated December 5,...
December 16, 2013 08:30 ET | Source: Hemispherx Biopharma, Inc.

Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season

PHILADELPHIA, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced that the company will accelerate its experimental program for a new...
December 09, 2013 08:00 ET | Source: Hemispherx Biopharma, Inc.

FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses

PHILADELPHIA, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that its Phase 1/2 clinical trial at the University of Alabama...
December 04, 2013 07:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers

PHILADELPHIA, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the Board has appointed Thomas Equels as the new Chief...
December 02, 2013 07:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma and the University of Pittsburgh Collaborate on a Novel Chemokine-Modulatory Program for Cancer Immunotherapies With Ampligen(R) as a Key Component

PHILADELPHIA, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that it is supporting the University of Pittsburgh's National...
November 19, 2013 08:00 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Sponsors Chronic Fatigue Syndrome Conference at Mount Sinai Medical Center in New York

PHILADELPHIA, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its sponsorship of the Conference on "Diagnosis, Treatments and New Developments in ME and CFS" ("Myalgic...
November 08, 2013 16:24 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2013

PHILADELPHIA, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended September 30, 2013. The net loss (including non-cash...
October 18, 2013 13:10 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma Reports on Annual Stockholder Meeting

PHILADELPHIA, Oct. 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE MKT:HEB) announced that it held its 2013 Annual Meeting of Stockholders on October 18, 2013. Final voting results will...
October 03, 2013 13:46 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma's 2013 Stockholder Annual Meeting Proposal 4 Removed From Stockholder Consideration

PHILADELPHIA, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company") announced that its Board of Directors has decided not to seek Stockholder approval regarding...
September 18, 2013 16:30 ET | Source: Hemispherx Biopharma, Inc.

Hemispherx Biopharma's 2013 Stockholder Annual Meeting Set

PHILADELPHIA, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company") will hold its Annual Meeting of stockholders on Friday, October 18, 2013, at 10 a.m. EDT, in...

Next Page keyboard_arrow_right